
FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.
FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.
Walker Barrier Systems builds eight mobile clean rooms for the Texas A&M Center for Innovation in Advanced Development and Manufacturing.
$2.6 billion transaction combines Patheon and DSM Pharmaceutical to create CDMO, DPx.
Almac expands technical, project, and operational resources in Asia.
Johnson Controls launches Integrated Laboratory Services for R&D facility operations and scientific productivity.
CPhI report shows R&D market diversifying with increased partnerships, mergers, and revenue sharing models.
Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.
Waters celebrates ten&$45;year anniversary of the ACQUITY UPLC System.
FDA approves the orphan drug Myalept for the treatment of leptin deficiency.
Novartis provides its second US university with Bexsero for the treatment of meningitis B.
Conference sessions, keynote events, exhibits, and poster sessions cover different aspects of bioprocessing.
Ecolab's Shield Medicare division will now be called Ecolab Contamination Control.
Agilent Technologies and Cell Line Genetics will collaborate on services for regenerative medicine and cancer research.
Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.
Cobra Biologics' GMP Compliance Certification has been extended to include QC testing.
Shimadzu's new Solution Center features additional research space.
Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.
Shimadzu's new Solution Center features additional research space.
Aesica appoints Ian Muir to the newly created position of commercial managing director.
Sartorius appoints Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division.
FDA plans to issue a number of new guidances in 2014 that will address drug development and manufacturing practices.
Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.
International Society for Pharmaceutical Engineering will continue strategic plan initiated by Nancy Berg; search begins for replacement.
EMD Millipore's expands its Emprove raw materials portfolio to include 400 products.
PharmaCell enters an agreement purchase TiGenix therapy production facility.
Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.
FDA adds Ranbaxy's Toansa, India facility to existing consent decree, prohibiting distribution of APIs from that location
In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.
The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.